Records containing: Pancreatic Acinar Cell Carcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-23Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)
-
CLINICAL_TRIALS study record update · 2026-04-23APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
-
CLINICAL_TRIALS study record update · 2026-04-13DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
-
CLINICAL_TRIALS study record update · 2026-04-13Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine
-
CLINICAL_TRIALS study record update · 2026-03-11Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-01-29SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives
-
CLINICAL_TRIALS study record update · 2026-01-07Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
-
CLINICAL_TRIALS study record update · 2018-02-07A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
-
CLINICAL_TRIALS study record update · 2016-03-09Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy